{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:32:31Z","timestamp":1793521951819,"version":"4.5.0"},"reference-count":86,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,27]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>One of the most remarkable achievements of the tyrosine kinase inhibitor (TKI) era has been the capacity to induce deep molecular remissions that are sustainable off therapy in patients with chronic myeloid leukemia (CML), that is, treatment-free remission (TFR). TFR was first described in a handful of patients within 3 to 4 years of imatinib approval. In 2004, TFR was tested in a small French pilot study, followed soon after by the French STIM and Australasian TWISTER studies. These early trials demonstrated that TFR was achievable but also showed that rapid relapse was equally likely. Perhaps the most critical observation was that relapsing patients could be rapidly and safely returned to deep molecular remission after restarting therapy, minimizing the risk associated with TFR attempts. Consensus criteria for TFR eligibility were established soon after those studies were reported. Over the past decade, TFR criteria have been broadened, key predictive markers of success identified, and overall safety of TFR in the wider clinical community confirmed. Despite this progress, TFR is still only achieved in a fraction of patients with CML globally. Over the next decade, the focus will be making TFR the mainstream pathway for as many patients as possible as well as scaling back the duration of therapy required. More potent, better targeted TKIs, and immune modulation will likely have a significant impact. Predictive assays should enable most patients who attempt TFR to do so with a high probability of success. Ultimately TFR should be seen as the first step on an ambitious pathway toward cure for patients with CML.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024026310","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T15:05:38Z","timestamp":1736175938000},"page":"921-930","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":25,"title":["The evolution of treatment-free remission"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0910-3730","authenticated-orcid":false,"given":"Timothy P.","family":"Hughes","sequence":"first","affiliation":[{"name":"1Cancer Program, Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia"},{"name":"2Department of Haematology, Royal Adelaide Hospital, Adelaide, SA, Australia"},{"name":"3School of Medicine, Faculty of Health Sciences, The University of Adelaide, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9452-1533","authenticated-orcid":false,"given":"Agnes S. M.","family":"Yong","sequence":"additional","affiliation":[{"name":"1Cancer Program, Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia"},{"name":"3School of Medicine, Faculty of Health Sciences, The University of Adelaide, Adelaide, SA, Australia"},{"name":"4Department of Haematology, Royal Perth Hospital, Perth, WA, Australia"},{"name":"5UWA Medical School, The University of Western Australia, Perth, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7171-2935","authenticated-orcid":false,"given":"David M.","family":"Ross","sequence":"additional","affiliation":[{"name":"1Cancer Program, Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia"},{"name":"2Department of Haematology, Royal Adelaide Hospital, Adelaide, SA, Australia"},{"name":"3School of Medicine, Faculty of Health Sciences, The University of Adelaide, Adelaide, SA, Australia"},{"name":"6College of Medicine and Public Health, Flinders University and Medical Centre, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2025032119423683700_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428190500407996","article-title":"Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?","volume":"47","author":"Goldman","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2025032119423683700_bib2","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1200\/JCO.2002.20.1.214","article-title":"Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa","volume":"20","author":"Mahon","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2025032119423683700_bib3","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/cncr.11223","article-title":"Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis","volume":"97","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"issue":"15","key":"2025032119423683700_bib4","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2025032119423683700_bib5","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.leukres.2003.10.017","article-title":"Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission","volume":"28","author":"Mauro","year":"2004","journal-title":"Leuk Res"},{"issue":"7","key":"2025032119423683700_bib6","first-page":"979","article-title":"Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation","volume":"90","author":"Merante","year":"2005","journal-title":"Haematologica"},{"issue":"7","key":"2025032119423683700_bib7","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1182\/blood-2004-04-1335","article-title":"Discontinuation of imatinib therapy after achieving a molecular response","volume":"104","author":"Cortes","year":"2004","journal-title":"Blood"},{"issue":"1","key":"2025032119423683700_bib8","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"issue":"10","key":"2025032119423683700_bib9","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","article-title":"Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR","volume":"24","author":"Ross","year":"2010","journal-title":"Leukemia"},{"issue":"11","key":"2025032119423683700_bib10","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"3","key":"2025032119423683700_bib11","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/ajh.25342","article-title":"Treatment-free remission with first- and second-generation tyrosine kinase inhibitors","volume":"94","author":"Cortes","year":"2019","journal-title":"Am J Hematol"},{"issue":"5","key":"2025032119423683700_bib12","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2025032119423683700_bib13","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-term follow-up of the French stop imatinib (STIM1) study in patients with chronic myeloid leukemia","volume":"35","author":"Etienne","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2025032119423683700_bib14","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1038\/s41375-018-0264-0","article-title":"Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells","volume":"32","author":"Ross","year":"2018","journal-title":"Leukemia"},{"issue":"6","key":"2025032119423683700_bib15","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"2025032119423683700_bib16","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"8","key":"2025032119423683700_bib17","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1038\/s41375-021-01173-w","article-title":"Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI","volume":"35","author":"Richter","year":"2021","journal-title":"Leukemia"},{"issue":"13","key":"2025032119423683700_bib18","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1182\/bloodadvances.2020001772","article-title":"Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission","volume":"4","author":"Rousselot","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"2025032119423683700_bib19","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2025032119423683700_bib20","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/bjh.13103","article-title":"Treatment-free remission after imatinib discontinuation is possible in paediatric patients with chronic myeloid leukaemia","volume":"168","author":"Giona","year":"2015","journal-title":"Br J Haematol"},{"issue":"4","key":"2025032119423683700_bib21","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/bjh.15826","article-title":"Discontinuation of imatinib in children with chronic myeloid leukaemia in sustained deep molecular remission: results of the STOP IMAPED study","volume":"185","author":"de Bruijn","year":"2019","journal-title":"Br J Haematol"},{"issue":"8","key":"2025032119423683700_bib22","doi-asserted-by":"crossref","first-page":"e29699","DOI":"10.1002\/pbc.29699","article-title":"Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia","volume":"69","author":"Shima","year":"2022","journal-title":"Pediatr Blood Cancer"},{"issue":"16","key":"2025032119423683700_bib23","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.3390\/cancers13164102","article-title":"Discontinuation of imatinib in children with chronic myeloid leukemia: a study from the International Registry of Childhood CML","volume":"13","author":"Millot","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"suppl 1","key":"2025032119423683700_bib24","article-title":"Successful treatment-free remission in low- and middle-income countries [abstract].","volume":"142","author":"Radich","year":"2023","journal-title":"Blood"},{"issue":"suppl 2","key":"2025032119423683700_bib25","doi-asserted-by":"crossref","first-page":"S298","DOI":"10.1016\/S2152-2650(22)01385-4","article-title":"Real world data of treatment free remission (TFR) in patients with chronic myeloid leukemia (CML) treated at a Tertiary Care Oncology Center in India","volume":"22","author":"Sarma","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2025032119423683700_bib26","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-024-01025-7","article-title":"A\u00a0successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements","volume":"14","author":"Bonifacio","year":"2024","journal-title":"Blood Cancer J"},{"issue":"8","key":"2025032119423683700_bib27","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.3324\/haematol.2018.205054","article-title":"Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice","volume":"104","author":"Fava","year":"2019","journal-title":"Haematologica"},{"issue":"7","key":"2025032119423683700_bib28","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study","volume":"129","author":"Rea","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2025032119423683700_bib29","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","article-title":"Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial","volume":"2","author":"Imagawa","year":"2015","journal-title":"Lancet Haematol"},{"issue":"3","key":"2025032119423683700_bib30","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/10428194.2019.1675879","article-title":"Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study","volume":"61","author":"Shah","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2025032119423683700_bib31","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M17-1094","article-title":"Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: results from a single-group, phase 2, open-label study","volume":"168","author":"Mahon","year":"2018","journal-title":"Ann Intern Med"},{"issue":"5","key":"2025032119423683700_bib32","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00432-018-2604-x","article-title":"Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study","volume":"144","author":"Ross","year":"2018","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"22","key":"2025032119423683700_bib33","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1002\/cncr.30885","article-title":"Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia","volume":"123","author":"Legros","year":"2017","journal-title":"Cancer"},{"issue":"4","key":"2025032119423683700_bib34","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/s41375-024-02145-6","article-title":"Treatment-free remission after a second TKI discontinuation attempt in patients with chronic myeloid leukemia re-treated with dasatinib-interim results from the DAstop2 trial","volume":"38","author":"Flygt","year":"2024","journal-title":"Leukemia"},{"issue":"5","key":"2025032119423683700_bib35","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/bjh.19058","article-title":"Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: treatment-free remission accomplished by dasatinib (TRAD) study","volume":"203","author":"Perusini","year":"2023","journal-title":"Br J Haematol"},{"issue":"11","key":"2025032119423683700_bib36","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.3324\/haematol.2011.048165","article-title":"Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features","volume":"96","author":"Ross","year":"2011","journal-title":"Haematologica"},{"issue":"5","key":"2025032119423683700_bib37","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.3324\/haematol.2019.234179","article-title":"Prolonged treatment-free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations","volume":"105","author":"Claudiani","year":"2020","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2025032119423683700_bib38","article-title":"Treatment-free remission after ponatinib cessation in chronic phase (CP) chronic myeloid leukemia (CML) patients. The ponastop observational study [abstract]","volume":"142","author":"Nicolini","year":"2023","journal-title":"Blood"},{"issue":"12","key":"2025032119423683700_bib39","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.3324\/haematol.2018.189787","article-title":"BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia","volume":"103","author":"Pagani","year":"2018","journal-title":"Haematologica"},{"issue":"9","key":"2025032119423683700_bib40","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41375-024-02327-2","article-title":"Treatment-free remission after third-line therapy with asciminib in chronic myeloid leukemia with an atypical e19a2 BCR::ABL1 transcript and T315I mutation","volume":"38","author":"Ernst","year":"2024","journal-title":"Leukemia"},{"issue":"16","key":"2025032119423683700_bib41","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1200\/JCO.23.01647","article-title":"European stop tyrosine kinase inhibitor trial (EURO-SKI) in chronic myeloid leukemia: final analysis and novel prognostic factors for treatment-free remission","volume":"42","author":"Mahon","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2025032119423683700_bib42","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ajh.26550","article-title":"Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors","volume":"97","author":"Haddad","year":"2022","journal-title":"Am J Hematol"},{"issue":"8","key":"2025032119423683700_bib43","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.3324\/haematol.2017.168740","article-title":"E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy","volume":"102","author":"Claudiani","year":"2017","journal-title":"Haematologica"},{"issue":"10","key":"2025032119423683700_bib44","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1002\/cncr.31977","article-title":"The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors","volume":"125","author":"D'Adda","year":"2019","journal-title":"Cancer"},{"issue":"9","key":"2025032119423683700_bib45","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.2020005514","article-title":"Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia","volume":"137","author":"Shanmuganathan","year":"2021","journal-title":"Blood"},{"issue":"25","key":"2025032119423683700_bib46","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1200\/JCO.2014.55.6910","article-title":"Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?","volume":"32","author":"Richter","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2025032119423683700_bib47","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.3324\/haematol.2021.280377","article-title":"Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia","volume":"107","author":"Flynn","year":"2022","journal-title":"Haematologica"},{"issue":"1","key":"2025032119423683700_bib48","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamaoncol.2020.5774","article-title":"Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia: a nonrandomized clinical trial","volume":"7","author":"Atallah","year":"2021","journal-title":"JAMA Oncol"},{"issue":"1","key":"2025032119423683700_bib49","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2019000120","article-title":"Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission","volume":"134","author":"Shanmuganathan","year":"2019","journal-title":"Blood"},{"issue":"12","key":"2025032119423683700_bib50","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.3324\/haematol.2022.280740","article-title":"Onset of blast crisis in chronic myeloid leukemia patients in treatment-free remission","volume":"107","author":"Dulucq","year":"2022","journal-title":"Haematologica"},{"issue":"6","key":"2025032119423683700_bib51","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1097\/HS9.0000000000000157","article-title":"Blast crisis of CML after TKI discontinuation in a patient with previous stable deep molecular response: is it safe to stop?","volume":"2","author":"Papalexandri","year":"2018","journal-title":"HemaSphere"},{"issue":"11","key":"2025032119423683700_bib52","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1002\/ajh.27073","article-title":"Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: final analysis of the TFR-PRO study","volume":"98","author":"Zambrotta","year":"2023","journal-title":"Am J Hematol"},{"issue":"7","key":"2025032119423683700_bib53","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.1016\/S2352-3026(17)30066-2","article-title":"De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial","volume":"4","author":"Clark","year":"2017","journal-title":"Lancet Haematol"},{"issue":"7","key":"2025032119423683700_bib54","doi-asserted-by":"crossref","first-page":"e375","DOI":"10.1016\/S2352-3026(19)30094-8","article-title":"De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial","volume":"6","author":"Clark","year":"2019","journal-title":"Lancet Haematol"},{"issue":"4","key":"2025032119423683700_bib55","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/jha2.550","article-title":"De-escalation or discontinuation of tyrosine kinase inhibitor in patients with chronic myeloid leukemia: a multicentral, open-label, prospective trial in China","volume":"3","author":"Luo","year":"2022","journal-title":"EJHaem"},{"issue":"4","key":"2025032119423683700_bib56","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/bjh.15629","article-title":"The effect on lymphocyte subsets of decreasing\/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: data from the DESTINY trial","volume":"185","author":"Austin","year":"2019","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"2025032119423683700_bib57","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.1182\/blood-2023-180131","article-title":"Full treatment-free remission outcome in patients with chronic myeloid leukemia in chronic phase following one year of nilotinib de-escalation: 96-week update of Dante study [abstract]","volume":"142","author":"Iurlo","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2025032119423683700_bib58","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1080\/10428194.2017.1337114","article-title":"Patient perceptions of treatment-free remission in chronic myeloid leukemia","volume":"59","author":"Villemagne Sanchez","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2025032119423683700_bib59","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1038\/s41375-020-0867-0","article-title":"Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs","volume":"34","author":"Sharf","year":"2020","journal-title":"Leukemia"},{"issue":"8","key":"2025032119423683700_bib60","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/s41375-024-02341-4","article-title":"Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI trial","volume":"38","author":"Efficace","year":"2024","journal-title":"Leukemia"},{"issue":"10","key":"2025032119423683700_bib61","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ajh.24120","article-title":"Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study","volume":"90","author":"Mori","year":"2015","journal-title":"Am J Hematol"},{"issue":"3","key":"2025032119423683700_bib62","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bjh.18277","article-title":"Highly sensitive droplet digital polymerase chain reaction for BCR::ABL1 messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment-free remission","volume":"198","author":"Lu","year":"2022","journal-title":"Br J Haematol"},{"issue":"22","key":"2025032119423683700_bib63","doi-asserted-by":"crossref","first-page":"6606","DOI":"10.1158\/1078-0432.CCR-18-3373","article-title":"Evaluation of residual disease and TKI duration are critical predictive factors for molecular recurrence after stopping imatinib first-line in chronic phase CML patients","volume":"25","author":"Nicolini","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"25","key":"2025032119423683700_bib64","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1182\/blood.2023021119","article-title":"Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy","volume":"142","author":"Pagani","year":"2023","journal-title":"Blood"},{"issue":"8","key":"2025032119423683700_bib65","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1038\/s41375-020-0882-1","article-title":"Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission","volume":"34","author":"Machova Polakova","year":"2020","journal-title":"Leukemia"},{"issue":"8","key":"2025032119423683700_bib66","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/ajh.27359","article-title":"BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: an individual participant data meta-analysis","volume":"99","author":"Kockerols","year":"2024","journal-title":"Am J Hematol"},{"issue":"4","key":"2025032119423683700_bib67","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/s41375-019-0647-x","article-title":"Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission","volume":"34","author":"Pagani","year":"2020","journal-title":"Leukemia"},{"issue":"9","key":"2025032119423683700_bib68","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors","volume":"129","author":"Hughes","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2025032119423683700_bib69","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/leu.2016.360","article-title":"Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia","volume":"31","author":"Ilander","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"2025032119423683700_bib70","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3324\/haematol.2017.165001","article-title":"Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study","volume":"102","author":"Rea","year":"2017","journal-title":"Haematologica"},{"issue":"4","key":"2025032119423683700_bib71","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/leu.2017.9","article-title":"Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML","volume":"31","author":"Schutz","year":"2017","journal-title":"Leukemia"},{"issue":"5","key":"2025032119423683700_bib72","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.clml.2018.03.004","article-title":"Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a second-line treatment","volume":"18","author":"Okada","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"2025032119423683700_bib73","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/bjh.16718","article-title":"Successful treatment-free remission in chronic myeloid leukaemia and its association\u00a0with reduced immune suppressors and increased natural killer cells","volume":"191","author":"Irani","year":"2020","journal-title":"Br J Haematol"},{"issue":"11","key":"2025032119423683700_bib74","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1182\/bloodadvances.2022008854","article-title":"Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia","volume":"7","author":"Irani","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2025032119423683700_bib75","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41375-023-02074-w","article-title":"Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation","volume":"38","author":"Huuhtanen","year":"2024","journal-title":"Leukemia"},{"issue":"3","key":"2025032119423683700_bib76","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1111\/bjh.15894","article-title":"Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia","volume":"186","author":"Ross","year":"2019","journal-title":"Br J Haematol"},{"issue":"6","key":"2025032119423683700_bib77","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/leu.2015.45","article-title":"Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia","volume":"29","author":"Burchert","year":"2015","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2025032119423683700_bib78","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2022-169324","article-title":"Efficacy of ropeginterferon alpha 2b in inducing treatment free remission in chronic\u00a0myeloid leukemia-an international, randomized phase III trial (ENDURE, CML-IX) of the German CML-Study Group [abstract]","volume":"140","author":"Burchert","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2025032119423683700_bib79","article-title":"Treatment free remission after nilotinib plus peg-interferon alpha induction and peg-interferon alpha maintenance therapy for newly diagnosed chronic myeloid leukemia patients; the Tiger trial [abstract]","volume":"142","author":"Hochhaus","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2025032119423683700_bib80","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1182\/blood-2021-146412","article-title":"Treatment-free remissions in newly diagnosed CP CML patients treated with the combination of nilotinib + pegylated interferon alpha 2a versus nilotinib alone in the national phase III petals trial [abstract]","volume":"138","author":"Nicolini","year":"2021","journal-title":"Blood"},{"key":"2025032119423683700_bib81","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.leukres.2017.03.003","article-title":"Is there immune surveillance against chronic myeloid leukaemia? Possibly, but not much","volume":"57","author":"Gale","year":"2017","journal-title":"Leuk Res"},{"issue":"2","key":"2025032119423683700_bib82","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2025032119423683700_bib83","first-page":"1621","article-title":"Cumulative incidence of treatment-free remission (TFR) for patients with chronic myeloid leukemia (CML): the Adelaide experience [abstract]","volume":"130","author":"Shanmuganathan","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2025032119423683700_bib84","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ajh.23923","article-title":"Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: results of the D-first study of Kanto CML Study Group","volume":"90","author":"Iriyama","year":"2015","journal-title":"Am J Hematol"},{"issue":"20","key":"2025032119423683700_bib85","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2025032119423683700_bib86","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa2400858","article-title":"Asciminib in newly diagnosed chronic myeloid leukemia","volume":"391","author":"Hochhaus","year":"2024","journal-title":"N\u00a0Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/9\/921\/2357257\/blood_bld-2024-026310-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/9\/921\/2357257\/blood_bld-2024-026310-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T16:46:21Z","timestamp":1742575581000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/9\/921\/534929\/The-evolution-of-treatment-free-remission"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":86,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,2,27]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024026310","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]}}}